Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Diagnostics group Yourgene Health booked a deeper annual loss, as investment spending and an impairment charge more than offset a rise in sales.
Pre-tax losses for the year through March amounted to £12.0 million, compared to year-on-year losses of £3.4 million.
Revenue rose 10% to £18.3 million, with Covid-related revenues and European non-invasive prenatal testing growth offsetting international pandemic headwinds.
Yourgene said it had invested £2.4 million of additional expenditure in future growth projects.
Losses also reflected a goodwill impairment charge arising from pandemic-related challenges in Asian markets.
In the first quarter of the current financial year, revenue had jumped 80% year-on-year to over £6 million with adjusted operating earnings estimated at around £0.7 million.
'The last financial year presented many operational and financial challenges to our business operations as a result of the Covid pandemic,' Yourgene said.
'Despite a challenging year operationally, we have maintained focus on our long-term objectives as well as effectively navigating the pandemic in the short-term, and as a result have established a broader platform with increased growth prospects to deliver shareholder value in the medium term. '